PT - JOURNAL ARTICLE AU - P.H.B. WILLEMSE AU - E.G.E. DE VRIES AU - M. KLOPPENBURG AU - D. L. FONTEIN AU - J. G. AALDERS AU - H. BOONSTRA TI - Carboplatin with cyclophosphamide in patients with advanced ovarian cancer: an efficacy and quality-adjusted survival analysis AID - 10.1046/j.1525-1438.1992.02050236.x DP - 1992 Sep 01 TA - International Journal of Gynecologic Cancer PG - 236--243 VI - 2 IP - 5 4099 - http://ijgc.bmj.com/content/2/5/236.short 4100 - http://ijgc.bmj.com/content/2/5/236.full SO - Int J Gynecol Cancer1992 Sep 01; 2 AB - The efficacy and toxicity of a combination of carboplatin and cyclophosphamide (CC) were studied in a group of 76 patients with advanced ovarian cancer. Progression-free (PFS) and overall survival were compared with a historical group of 65 patients treated with CAP-5 (cyclophosphamide, adriamycin, cisplatin). Subjective toxicity was compared by the measurement of TWiST, the Time Without Symptoms of Disease or Treatment. Of 75 evaluable patients treated with CC, 18 (24%) had a pathologically complete remission (pCR), and 31 (41%) a partial remission (PR). CC led to leukopenia grade III in 38% and grade IV in 3% of 421 treatment cycles. Thrombocytopenia grade III was seen after 7% and grade IV after 2% of cycles. Treatment delay occurred in 11.5% and dose reduction in 21% of cycles. Nephro- or neurotoxicity did not occur. After a median follow-up of 18 months, the median PFS was 24 months and the overall survival was 25 months. Median duration of TWiST was 22 versus 10 months after CAP-5 (P < 0.01). Compared with historical controls, treatment with CC is equivalent to CAP-5. It is free of nephro- and neurotoxicity, but is more myelosuppressive. Quality of life, measured by TWiST, is significantly better during CC. As a consequence of its equivalent efficacy, but lower subjective toxicity, carboplatin should replace cisplatin in treating patients with advanced ovarian cancer.